1
|
Cantini L, Mentrasti G, Lo Russo G, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, La Verde N, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo E, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D’Emilio V, Cona M, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri M, Emili R, Roca E, Migliore A, Galassi T, Rocchi M, Berardi R. Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’. ESMO Open 2022; 7:100471. [PMID: 35378403 PMCID: PMC8973259 DOI: 10.1016/j.esmoop.2022.100471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
2
|
Cantini L, Mentrasti G, Russo GL, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, Gori S, Verde NL, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D'Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri V, Emili R, Roca E, Migliore A, Galassi T, Rocchi MLB, Berardi R. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. ESMO Open 2022; 7:100406. [PMID: 35219245 PMCID: PMC8810307 DOI: 10.1016/j.esmoop.2022.100406] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 01/19/2022] [Accepted: 01/23/2022] [Indexed: 12/18/2022] Open
Abstract
Introduction COVID-19 has disrupted the global health care system since March 2020. Lung cancer (LC) patients (pts) represent a vulnerable population highly affected by the pandemic. This multicenter Italian study aimed to evaluate whether the COVID-19 outbreak had an impact on access to cancer diagnosis and treatment of LC pts compared with pre-pandemic time. Methods Consecutive newly diagnosed LC pts referred to 25 Italian Oncology Departments between March and December 2020 were included. Access rate and temporal intervals between date of symptoms onset and diagnostic and therapeutic services were compared with the same period in 2019. Differences between the 2 years were analyzed using the chi-square test for categorical variables and the Mann–Whitney U test for continuous variables. Results A slight reduction (−6.9%) in newly diagnosed LC cases was observed in 2020 compared with 2019 (1523 versus 1637, P = 0.09). Newly diagnosed LC pts in 2020 were more likely to be diagnosed with stage IV disease (P < 0.01) and to be current smokers (someone who has smoked more than 100 cigarettes, including hand-rolled cigarettes, cigars, cigarillos, in their lifetime and has smoked in the last 28 days) (P < 0.01). The drop in terms of new diagnoses was greater in the lockdown period (percentage drop −12% versus −3.2%) compared with the other months included. More LC pts were referred to a low/medium volume hospital in 2020 compared with 2019 (P = 0.01). No differences emerged in terms of interval between symptoms onset and radiological diagnosis (P = 0.94), symptoms onset and cytohistological diagnosis (P = 0.92), symptoms onset and treatment start (P = 0.40), and treatment start and first radiological revaluation (P = 0.36). Conclusions Our study pointed out a reduction of new diagnoses with a shift towards higher stage at diagnosis for LC pts in 2020. Despite this, the measures adopted by Italian Oncology Departments ensured the maintenance of the diagnostic-therapeutic pathways of LC pts. The COVID-19 outbreak had an impact on access to lung cancer (LC) diagnosis and treatment. A slight reduction (−6.9%) in newly diagnosed LC cases was observed in 2020 compared with 2019. Newly diagnosed LC pts in 2020 were more likely to be diagnosed with stage IV disease. The Italian Oncology Departments ensured the maintenance of the diagnostic-therapeutic pathways of LC pts. A reverse migration from high-volume to low-volume cancer centers was noted during the pandemic.
Collapse
Affiliation(s)
- L Cantini
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy. https://twitter.com/LucaCantiniMD
| | - G Mentrasti
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - G L Russo
- Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - D Signorelli
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
| | - G Pasello
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy
| | - E Rijavec
- Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - M Russano
- Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy
| | - L Antonuzzo
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
| | - D Rocco
- Department of Pulmonology and Oncology, AORN dei Colli Monaldi, Naples, Italy
| | - R Giusti
- UOC Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Università La Sapienza, Rome, Italy
| | - V Adamo
- Oncologia Medica, A.O.Papardo & Università di Messina, Messina, Italy
| | - C Genova
- UOC Clinica di Oncologia Medica, IRCCS Ospedale San Martino, Department of Internal Medicine and Medical Specialties (DIMI), Università degli Studi di Genova, Genoa, Italy
| | - A Tuzi
- Oncologia Medica, ASST Sette Laghi, Varese, Italy
| | - A Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori "Fondazione G Pascale", IRCCS, Naples, Italy
| | - S Gori
- UOC Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy
| | - N La Verde
- Department of Oncology, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milan, Italy
| | - R Chiari
- Medical Oncology, Ospedali Riuniti Padova Sud, Monselice, Italy
| | - A Cortellini
- Medical Oncology, St Salvatore Hospital, L'Aquila, Italy
| | - V Cognigni
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - F Pecci
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - A Indini
- Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - A De Toma
- Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - E Zattarin
- Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - S Oresti
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy
| | - E G Pizzutilo
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy
| | - S Frega
- Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy
| | - E Erbetta
- Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padua, Italy
| | - A Galletti
- Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy
| | - F Citarella
- Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy
| | - S Fancelli
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
| | - E Caliman
- Medical Oncology Unit, Careggi University Hospital, Florence, Italy
| | - L Della Gravara
- Dipartment of Experimental Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - U Malapelle
- Department of Public Health, Università degli Studi di Napoli "Federico II", Naples, Italy
| | - M Filetti
- UOC Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Università La Sapienza, Rome, Italy
| | - M Piras
- UOC Oncologia Medica, Azienda Ospedaliero Universitaria Sant'Andrea, Università La Sapienza, Rome, Italy
| | - G Toscano
- Oncologia Medica, A.O.Papardo, Messina, Italy
| | - L Zullo
- UOC Oncologia Medica 2, IRCCS Ospedale San Martino, Genoa, Italy
| | - M De Tursi
- Department of Innovative Technologies in Medicine & Dentistry, Università G. D'Annunzio, Chieti-Pescara, Chieti, Italy
| | - P Di Marino
- Department of Innovative Technologies in Medicine & Dentistry, Università G. D'Annunzio, Chieti-Pescara, Chieti, Italy
| | - V D'Emilio
- UOC Pneumologia, Ospedale Mazzoni, Ascoli Piceno, Italy
| | - M S Cona
- Department of Oncology, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milan, Italy
| | - A Guida
- Oncologia Medica e Traslazionale, AO Santa Maria, Terni, Italy
| | - A Caglio
- Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy
| | - F Salerno
- Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy
| | - G Spinelli
- UOC Territorial Oncology, University "Sapienza", AUSL Latina, Cds Aprilia, Aprilia, Italy
| | - C Bennati
- Department of Onco-Hematology, AUSL della Romagna, Ravenna, Italy
| | - F Morgillo
- UOC Oncologia ed Ematologia, Department of Precision Medicine, Università degli studi della Campania "Luigi Vanvitelli", Naples, Italy
| | - A Russo
- Oncologia Medica, A.O.Papardo, Messina, Italy
| | - C Dellepiane
- UOC Oncologia Medica 2, IRCCS Ospedale San Martino, Genoa, Italy
| | - I Vallini
- Oncologia Medica, ASST Sette Laghi, Varese, Italy
| | - V Sforza
- Thoracic Medical Oncology, Istituto Nazionale Tumori "Fondazione G Pascale", IRCCS, Naples, Italy
| | - A Inno
- UOC Oncologia Medica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy
| | - F Rastelli
- UOC Oncologia, Ospedale Mazzoni, Ascoli Piceno, Italy
| | - V Tassi
- Chirurgia Toracica, AO Santa Maria, Terni, Italy
| | - L Nicolardi
- Medical Oncology, Ospedali Riuniti Padova Sud, Monselice, Italy
| | - V Pensieri
- Medical Oncology, St Salvatore Hospital, L'Aquila, Italy
| | - R Emili
- Operative Oncology Unit, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy
| | - E Roca
- Thoracic Oncology - Lung Unit, Pederzoli Hospital, Peschiera Del Garda, Italy
| | - A Migliore
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - T Galassi
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy
| | - M L Bruno Rocchi
- Biomolecular Sciences Department, University of Urbino, Urbino, Italy
| | - R Berardi
- Department of Medical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, Ancona, Italy.
| |
Collapse
|
3
|
Berardi R, Mentrasti G, Crocetti S, La Verde N, Chiari R, Cona M, Nicolardi L, De Filippis C, Oldani S, Pecci F, Venanzi F, Rocchi M, Savini A, Cantini L, Pistelli M. 1609P COVID-19 outbreak repercussions on breast cancer diagnoses and access to treatment: Preliminary data from the COVID-DELAY study. Ann Oncol 2021. [PMCID: PMC8454380 DOI: 10.1016/j.annonc.2021.08.1602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
4
|
Cantini L, Mentrasti G, La Verde N, Cona M, Chiari R, Martinelli E, Morgillo F, Nicolardi L, Cortellini A, Pensieri V, Cognigni V, Pinterpe G, Galassi T, Pecci F, Mazzanti P, Di Pietro Paolo M, Giampieri R, Berardi R. 35P Lung cancer diagnosis and continuum of care: How did the COVID-19 outbreak impact? Data from an Italian multicenter study. J Thorac Oncol 2021. [PMCID: PMC8970659 DOI: 10.1016/s1556-0864(21)01877-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
5
|
Lenci E, Cantini L, Rinaldi S, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Ranallo N, Lupi A, Paoloni F, Cortellini A, Ficorella C, Chiari R, Di Maio M, Aerts J, Dingemans A, Nicolardi L, Caglio A, Aerts S, Berardi R. FP12.06 GRIm-Score Variations Predict Outcome in Metastatic NSCLC Patients Treated with First-Line Pembrolizumab. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
6
|
Chierigo P, Nicolardi L, Rahmati M, Lazzarotto M, Brotza D, Bassan F, Franzolin N. Testicular Localization of Extranodal Multifocal Non-Hodgkin Lymphoma. Report of Two Cases, Review of the Literature and Clinical Considerations. Urologia 2009. [DOI: 10.1177/039156030907600220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The aim of our study is to describe two cases of testicular localization of non-Hodgkin Lymphoma associated with the involvement of other extranodal organs, and to investigate the possible causes of this association according to the evidences found in literature. Non-Hodgkin Lymphoma is extranodal in 25% of cases. Most of the times the organs involved are stomach, bowel, skin, central nervous system. About urological localizations, the most common is testis. Very rare is to find lymphoma in kidney, prostate, urinary bladder, and ureter. Testicular lymphoma is about 5% of testis malignancies; it is more frequent in the 7th and in the 8th decade. Metastases of testicular non-Hodgkin lymphoma are described also many years later, and also in distant organs. Primary forms are usually “diffuse large B cell”, a high-grade histotype; metastatic ones often show Burkitt cells. The standard therapy used for non-Hodgkin Lymphomas does not reach testis and central nervous system, so that these sites are called “Therapeutic Shrines”. Therefore, in order to prevent testicular localization, it is necessary to use radiotherapy, and for nervous system prophylaxis it is necessary to administer intrathecal chemotherapy. More than one localization of non-Hodgkin lymphoma simultaneously found may indicate not only a metastatic spread, but also a multicentric origin. We describe two patients who had one testis removed because of a big mass that turned out to be a non-Hodgkin lymphoma. The first patient had been treated for a non-Hodgkin lymphoma of maxillary sinus 20 months before. The second patient showed contemporary involvement of other organs. In both cases the different localizations of non-Hodgkin lymphoma showed the same histological features and cellular immunophenotype. It is important to underline that in the former patient staging TC, repeated many times, had always been negative, but physical examination of testis had been omitted, so that sinonasal localization, assumed to be the first one, really might have been the spread of an undetected testis lymphoma. In conclusion, in case of extranodal non-Hodgkin lymphoma or any other malignancies, manual or ultrasound examination of testis should never be omitted, because standard techniques of staging (TC, RMN, PET) cannot explore this organ.
Collapse
Affiliation(s)
- P. Chierigo
- Unità Operativa Complessa di Urologia, Dipartimento di Chirurgia, Ospedale De Lellis, Schio (VI)
| | - L. Nicolardi
- Unità Operativa Complessa di Oncologia, Dipartimento di Medicina, Ospedale Boldrini, Thiene (VI) Azienda Ulss 4 “Alto Vicentino (Thiene – Schio)
| | - M. Rahmati
- Unità Operativa Complessa di Urologia, Dipartimento di Chirurgia, Ospedale De Lellis, Schio (VI)
| | - M. Lazzarotto
- Unità Operativa Complessa di Urologia, Dipartimento di Chirurgia, Ospedale De Lellis, Schio (VI)
| | - D. Brotza
- Unità Operativa Complessa di Urologia, Dipartimento di Chirurgia, Ospedale De Lellis, Schio (VI)
| | - F. Bassan
- Unità Operativa Complessa di Oncologia, Dipartimento di Medicina, Ospedale Boldrini, Thiene (VI) Azienda Ulss 4 “Alto Vicentino (Thiene – Schio)
| | - N. Franzolin
- Unità Operativa Complessa di Urologia, Dipartimento di Chirurgia, Ospedale De Lellis, Schio (VI)
| |
Collapse
|
7
|
Chierigo P, Nicolardi L, Rahmati M, Lazzarotto M, Brotza D, Bassan F, Franzolin N. [Testicular localization of extranodal multifocal non-Hodgkin lymphoma. Report of two cases, review of the literature and clinical considerations]. Urologia 2009; 76:133-136. [PMID: 21086316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The aim of our study is to describe two cases of testicular localization of non- Hodgkin Lymphoma associated with the involvement of other extranodal organs, and to investigate the possible causes of this association according to the evidences found in literature. Non-Hodgkin Lymphoma is extranodal in 25% of cases. Most of the times the organs involved are stomach, bowel, skin, central nervous system. About urological localizations, the most common is testis. Very rare is to find lymphoma in kidney, prostate, urinary bladder, and ureter. Testicular lymphoma is about 5% of testis malignancies; it is more frequent in the 7th and in the 8th decade. Metastases of testicular non-Hodgkin lymphoma are described also many years later, and also in distant organs. Primary forms are usually "diffuse large B cell", a high-grade histotype; metastatic ones often show Burkitt cells. The standard therapy used for non-Hodgkin Lymphomas does not reach testis and central nervous system, so that these sites are called "Therapeutic Shrines". Therefore, in order to prevent testicular localization, it is necessary to use radiotherapy, and for nervous system prophylaxis it is necessary to administer intrathecal chemotherapy. More than one localization of non-Hodgkin lymphoma simultaneously found may indicate not only a metastatic spread, but also a multicentric origin. We describe two patients who had one testis removed because of a big mass that turned out to be a non-Hodgkin lymphoma. The first patient had been treated for a non-Hodgkin lymphoma of maxillary sinus 20 months before. The second patient showed contemporary involvement of other organs. In both cases the different localizations of non-Hodgkin lymphoma showed the same histological features and cellular immunophenotype. It is important to underline that in the former patient staging TC, repeated many times, had always been negative, but physical examination of testis had been omitted, so that sinonasal localization, assumed to be the first one, really might have been the spread of an undetected testis lymphoma. In conclusion, in case of extranodal non- Hodgkin lymphoma or any other malignancies, manual or ultrasound examination of testis should never be omitted, because standard techniques of staging (TC, RMN, PET) cannot explore this organ.
Collapse
|
8
|
Tosoni A, Franceschi E, Blatt V, Bartolini S, Magrini E, Spagnolli F, Pozzati E, Nicolardi L, Ermani M, Brandes A. 2507 POSTER Temozolomide (TMZ) concomitant to radiotherapy (RT) plus 12 cycles of maintenance chemotherapy in newly diagnosed GBM: is more better? EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70910-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
9
|
Manente P, Vicario G, Scelzi E, Sartor L, Nicolardi L, Rizzo A, Pinarello A, Spaliviero B, Sbeghen R. Correlation of preoperative citology/histology in radiologically detected lesions and histologic findings at excision. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1552 Background: The major techniques used to diagnose breast abnormality has been for many years fine-needle aspiration (FNA) cytology and core needle biopsy (CNB) and more recently vacuum-assisted core biopsy (VACB). These techniques are accurate and allow definitive therapeutic surgery. The aim of our study was to detemine whether cytology/histologic findings mach histologic findings at excision. Methods: In our Institution, between January 2004 and June 2006, 43,138 mammographic exams were performed. 1,012 patients had patological lesions at mammography: 617 FNA cytology ( C due to European guidelines for breast cancer screening assessment) and 395 CNB/VACB (B) were performed. Patients with respectively suspicious and malignant FNA cytology (C4 and C5) and respectively uncertain malignant potential, suspicious and malignant histology (B3, B4 and B5) underwent to surgery. Results: The number of cancer identified by FNA cytology was 158 and the number of cancer identified by CNB/VACB was 253. The correlation of preoparative citology/histology with definitive histology had showed: false negative rate respectively 0.79% for histology (B) and 3.16% for cytology (C). False positive rate was respectively 0.4% for B and 0.63 for C. Complete sensitivity was 98.2% for B and 89.87% for C. Absolute sensitivity was 90.51% for B and 76.58% for C. Conclusions: Our data demostrated very high performance of diagnostic preoperative procedures due to multidisciplinary approach between the radiologists, the clinicians and the pathologists. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Manente
- City Hospital, Castelfranco Veneto, Italy
| | - G. Vicario
- City Hospital, Castelfranco Veneto, Italy
| | - E. Scelzi
- City Hospital, Castelfranco Veneto, Italy
| | - L. Sartor
- City Hospital, Castelfranco Veneto, Italy
| | | | - A. Rizzo
- City Hospital, Castelfranco Veneto, Italy
| | | | | | - R. Sbeghen
- City Hospital, Castelfranco Veneto, Italy
| |
Collapse
|
10
|
Nicolardi L, Bertorelle R, Bonaldi L, Compostella A, Roma A, Tebaldi E, Pession A, Reni M, Franceschi E, Ghimenton C. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and relation to 1p/19q loss in low grade gliomas: A GICNO study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.20064] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
20064 Background: 1p and 19q deletions have been associated with a favorable response to chemotherapy and a good prognosis in patients (pts) with oligodendroglioma. MGMT promoter methylation has been associated with a longer survival in pts with glioblastoma who receive alkylating agents. As yet, there are no data on the expression of MGMT, and on the relationship between 1p/19q deletions and MGMT promoter methylation in low grade glioma (LGG). Methods: Pts that received a first line chemotherapy regimen with temozolomide for progressive LGG were enrolled in the study, designed to investigate the correlation between MGMT methylation status and 1p/19q deletions in this setting. 1p/19q deletions were analysed by FISH, and MGMT promoter methylation by methylation specific PCR (MSP). Results: Seventy-five pts (26 females, 49 males; median age 42 years: range 22–68 years) were accrued. Of these, 48 (64%) had oligodendrogliomas (O), 19 (25.3%) astrocytomas (A), and 8 (10.6%) oligoastrocytomas (OA); 44 (58.7%) had a history of epilepsy, 41 (54.7%) had a frontal tumor localization, 27 (36%) had MRI contrast enhancing lesions, and 35 (46.7%) had been pre-treated with radiotherapy. 1p/19q deletions, evaluable in 58 pts (77.3%), were both present in 36 pts (62%), (3 being A and 2 OA); 18 pts (31%) had no loss; 1 pt (1.7%) had 1p loss; 3 pts (5.2%) 19q loss. Combined 1p and 19q loss was not correlated with a frontal localization (p = 0.12), median age (0.47) and/or gender (0.62). MGMT promoter methylation, present in 17 (56.6%) of 30 assessable cases, was significantly associated with combined 1p/19q deletions (p = 0.03). MGMT promoter methylation was not significantly associated with age (p = 0.46), gender (p = 0.2), tumor localization (p = 0.12) and/or histology (0.37). Conclusions: 1p/19q deletions are strictly correlated to histology and to MGMT promoter methylation; further prospective trials are required to clarify the impact of these molecular signatures on clinical outcome. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Nicolardi
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| | - R. Bertorelle
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| | - L. Bonaldi
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| | - A. Compostella
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| | - A. Roma
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| | - E. Tebaldi
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| | - A. Pession
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| | - M. Reni
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| | - E. Franceschi
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| | - C. Ghimenton
- IOV-Azienda Ospedale Università di Padova, Padova, Italy; Bellaria Hospital, Bologna, Italy; San Raffaele Hospital Scientific Institute, Milano, Italy; Verona Hospital, Verona, Italy
| |
Collapse
|
11
|
Brandes AA, Cavallo G, Tosoni A, Ermani M, Franceschi E, Scopece L, Ghimenton C, Blatt V, Nicolardi L, Crinò L. Temozolomide (TMZ) for progressive primitive brain tumors: safety at 75 mg/m 2 a day for 21 days every 28: A GICNO (Italian Neuro-Oncology Group) study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.1541] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. A. Brandes
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| | - G. Cavallo
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| | - A. Tosoni
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| | - M. Ermani
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| | - E. Franceschi
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| | - L. Scopece
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| | - C. Ghimenton
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| | - V. Blatt
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| | - L. Nicolardi
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| | - L. Crinò
- Azienda Ospedale-Università, Padova, Italy; Bellaria Hosp, Bologna, Italy; Verona Hosp, Verona, Italy
| |
Collapse
|
12
|
Brandes AA, Tosoni A, Amistà P, Nicolardi L, Grosso D, Berti F, Ermani M. How effective is BCNU in recurrent glioblastoma in the modern era?: A phase II trial. Neurology 2004; 63:1281-4. [PMID: 15477552 DOI: 10.1212/01.wnl.0000140495.33615.ca] [Citation(s) in RCA: 108] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND The initial studies on nitrosoureas were performed >30 years ago. These drugs remain the standard chemotherapy for glioblastoma. However, because the criteria used to evaluate the activity of nitrosoureas in a neuro-oncologic setting have changed, new data on their activity are needed. METHODS The authors conducted a phase II study on 40 patients with recurrent glioblastoma following surgery and standard radiotherapy. They analyzed progression-free survival at 6 months (PFS-6), time to progression (TTP), response rate, and toxicity. Patients were treated with 80 mg/m2 carmustine on days 1 to 3, every 8 weeks for a maximum of six cycles. RESULTS Median TTP was 13.3 weeks (95% CI, 10.26 to 16.86 weeks), and PFS-6 was 17.5% (95% CI, 8.9 to 34.3). Response to chemotherapy, age < or =40 years, and performance status > or =90 were significant prognostic factors for TTP; however, with multivariate analysis, only response to chemotherapy was significant. The major side effects were reversible hematologic and long-lasting hepatic and pulmonary toxicity. CONCLUSION The activity of this BCNU regimen is comparable with that reported in the past and with the newest therapies, such as temozolomide. However, BCNU toxicity is high and recovery is slow, thus compromising the administration of further drugs in patients with progressive disease.
Collapse
Affiliation(s)
- A A Brandes
- Department of Medical Oncology, Azienda Ospedale-Università, Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy.
| | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
The prevalence of HCV antibodies was assessed in 407 health-care workers and in 253 control subjects by means of immunoassays based on recombinant antigens. The seroprevalence in the study group was fairly low (1.2%) and not statistically different from that of controls (0.8%). The relation of HBV and HCV infections was evaluated in 83 health-care workers and in 82 controls: in both groups anti-HCV positivity was weakly related (p less than 0.05) to the HBV infection. HCV infection was associated with working in high risk wards (4/5 cases) and with report of accidental needle pricks (4/5 cases). As evaluated by means of the available markers, HCV infections in health-care workers seem to be rare.
Collapse
Affiliation(s)
- C Campello
- Istituto di Igiene Università degli Studi di Verona, Policlinico Borgo Roma, Italy
| | | | | | | | | | | |
Collapse
|